Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating imsidolimab (ANB019) for acne vulgaris has completed and its efficacy and safety results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• Imsidolimab (ANB019) (imsidolimab)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Acne Vulgaris | Phase 2 | Status: COMPLETED | Results posted: 2023-06-15